Cite
HARVARD Citation
Califano, R. et al. (n.d.). 49OIMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) + carboplatin + etoposide (CP/ET) in extensive-stage SCLC (ES-SCLC). Annals of oncology. p. . [Online].